NCT03310450 (TdBTS) is a clinical trial of 140kms cycling in Heart Arrest, sponsored by Universitas Negeri Semarang.

Who is sponsoring NCT03310450?

NCT03310450 is sponsored by Universitas Negeri Semarang.

What drugs are being tested in NCT03310450?

Interventions in NCT03310450: 140kms cycling.

What condition does NCT03310450 study?

NCT03310450 studies Heart Arrest, Sport Injury, Inflammatory Response, Oxidative Stress.

Is NCT03310450 still recruiting?

NCT03310450 is currently completed. Last updated 10 October 2019.

Are results published for NCT03310450?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2019-10-10 · How we verify

NCT03310450: TdBTS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Tour de Borobudur Troponin Study on Predictors and Synergistic Role of MDA and Hs-CRP Levels

Completed Results posted Last updated 10 October 2019

What this trial tests

trial testing 140kms cycling in Heart Arrest in 94 participants. Completed in 5 May 2018.

Timeline

28 October 2017

Primary endpoint
11 November 2017

5 May 2018

Quick facts

Lead sponsor	Universitas Negeri Semarang
Status	Completed
Study type	OBSERVATIONAL
Enrollment	94
Start date	28 October 2017
Primary completion	11 November 2017
Estimated completion	5 May 2018
Sites	1 location across Indonesia

Drugs / interventions tested

140kms cycling

Conditions studied

Heart Arrest — all drugs for Heart Arrest →
Sport Injury — all drugs for Sport Injury →
Inflammatory Response — all drugs for Inflammatory Response →
Oxidative Stress — all drugs for Oxidative Stress →

Sponsor

Universitas Negeri Semarang — full company profile →

Who can join

Adults 25 to 55, male only, with Heart Arrest or Sport Injury. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Cardiac Troponin I (cTnI) Primary · immediate after TdB 2017 cycling touring within less than 5 min

specific protein to determine cardiac injury

Group	Value	95% CI
Group 140kms Cycling	6.6	± 46.6
Group 100kms Cycling	10.1	± 10.44
Group 240kms Cycling	25.0	± 61.39

Malondialdehyde (MDA) Primary · immediate after TdB 2017 cycling touring within less than 5 min

oxydative stress marker

Group	Value	95% CI
Group 140kms Cycling	206.1	± 116.84
Group 100kms Cycling	196.4	± 68.59
Group 240kms Cycling	231.2	± 105.54

High Sensitivity C Reactive Protein (Hs-CRP) Secondary · immediate after TdB 2017 cycling touring within less than 5 min

a biomarker that represents the inflammation process

Group	Value	95% CI
Group 140kms Cycling	454	± 286.5
Group 100kms Cycling	335	± 375.1
Group 240kms Cycling	350	± 332.6

Number of Participants With Pathological ECG Appearance Secondary · immediate after TdB 2017 cycling touring within less than 5 min

Number of Participants with Pathological ECG Appearance. Pathological ECG appearance was the results of the ECG test describing one of the pathological appearances in ECG i.e.: 1. The pathological rhythm which is may consist of Atrial Flutter, Atrial Fibrillation, Supraventricular Tachycardia, Ventricular Fibrillation, First Degree Heart Block, Second Degree Heart Block, Type 1 - Mobitz I, Second Degree Heart Block, Type 2 - Mobitz II, Third Degree Heart Block, or other pathological rhythm appearances 2. Pathological ST-segment i.e. ST elevation (early repolarization), or another form 3. Pat

Group	Value	95% CI
Group 140kms Cycling	0
Group 100kms Cycling	0
Group 240kms Cycling	0

Sponsor's own description

Prospective observational study to determine predictors that related to cardiac troponin I (cTnI) release, malondialdehyde (MDA) and high sensitivity C Reactive Protein (hs-CRP) after Tour de Borobudur (TdB) 2017

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Heart Arrest

Currently open trials in the same condition.

NCT03544489 — Effectiveness of Exercise After an ICD · Phase 2, PHASE3 · recruiting
NCT06159764 — National Registry of Cardioneuroablation in Recurrent Reflex Syncope · recruiting
NCT06401707 — PeRampanel fOr Status ePilEpticus pRophylaxis Post-cardiac Arrest · Phase 2 · recruiting
NCT05321459 — Predictive Outcome in Comatose Patients · recruiting
NCT05851391 — buRst-supprESsion TO Stop Refractory Status Epilepticus Post-cardiac Arrest · Phase 2 · recruiting

Other Universitas Negeri Semarang trials

Trials by the same sponsor.

NCT03899454 — Garcinia Mangostana L Rind and Solanum Lycopersicum Fructus Trial to Prevent Exercise-induced Oxidative Stress · Phase 2, PHASE3 · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03310450 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Universitas Negeri Semarang
Last refreshed: 10 October 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03310450.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing